Actovegin equal to performance enhancing drug doping: fact or fiction?

View/ open
Author
Lee, Paul
Kwan, Alvin
Smith, Paul M.
Brock, James
Nokes, Len
Date
2016-10-23Acceptance date
2016-10-13
Type
Article
Publisher
OMICS International
ISSN
2157 - 7552
Metadata
Show full item recordAbstract
Actovegin is a biological drug that has been used for the treatment of sports muscle injuries. Several in vitro studies have shed light on potential mechanisms of action and the drug has consistently demonstrated its potential to reduce return from injury time for muscle tears in elite athletes. Yet it was banned for a time under the International Olympic Committee (IOC) as a blood doping agent, this ban was based on presumptuous conclusions and subsequently lifted after no indisputable evidence could be provided. This editorial aims to provide readers with some of the key, objective facts relating to Actovegin and then based on this, will offer an informed opinion on its role in sports medicine. We also hope to highlight the importance of evidence-based medicine, particularly in the volatile field of Sports Medicine, and the need for facts, not fiction.
Journal/conference proceeding
Journal of Tissue Science and Engineering;1000179
Citation
Lee, P.Y.F., Kwan, A.P., Smith, P.M., Brock, J. and Nokes, L.D.M. (2016) 'Actovegin eguals performance enhancing drug doping: fact or fiction?', Journal of Tissue Science and Engineering, 7: 179, doi: 10.4172/2157-7552.1000179
Description
Editorial article published open access in Journal of Tissue Science and Engineering available at http://dx.doi.org/10.4172/2157-7552.1000179
Sponsorship
Cardiff Metropolitan University (Grant ID: Cardiff Metropolian (Internal))
Collections
- Sport Research Groups [951]